Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00457951 · ClinicalTrials.gov registry record · Phase 2
A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD
A Phase 2 study, sponsored by Jazz Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 158
- Enrollment target
NCT00457951 is a Phase 2 study that was terminated before completion, run by Jazz Pharmaceuticals. The registered enrollment target is 158 participants.
The verdict
NCT00457951, a Phase 2 study, was terminated before completion, sponsored by Jazz Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 158 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether ODSH, when added to conventional treatment, is more effective in treating COPD exacerbations than conventional therapy alone.
Interventions
- DRUG ODSH
- DRUG Open-Label
- DRUG Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2007-04 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00457951
The ClinicalTrials.gov registry entry for NCT00457951 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which ODSH is the first listed.
NCT00457951 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00457951 about?
NCT00457951 is a clinical study titled "A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD". The purpose of this study is to determine whether ODSH, when added to conventional treatment, is more effective in treating COPD exacerbations than conventional therapy alone.
What is the current status of trial NCT00457951?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 158 participants. The study started on 2007-04. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00457951?
The interventions under investigation include: ODSH (DRUG), Open-Label (DRUG), Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride (DRUG).
Who is sponsoring clinical trial NCT00457951?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.